HealthcareServices

Global Acquired Immunodeficiency Syndrome (AIDS) Industry Trends and Market Forecast 2026–2030

February 19, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the acquired immunodeficiency syndrome (aids) market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Acquired Immunodeficiency Syndrome (AIDS) Market from 2026 to 2030?

The market size for acquired immunodeficiency syndrome (aids) has experienced substantial growth in recent years. It is projected to expand from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. Historically, this expansion has been driven by the widespread prevalence of HIV infections globally, enhanced awareness and screening initiatives, government-supported HIV treatment programs, the introduction of first-generation antiretroviral drugs, and an increasing incidence of opportunistic infections.

The acquired immunodeficiency syndrome (aids) market is set to experience significant expansion over the next few years. It is projected to reach $43.28 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.1%. This anticipated growth during the forecast period is driven by factors such as the development of innovative next-generation antiretroviral therapies, the widening reach of PrEP and PEP programs, advancements in HIV vaccine research, the increasing adoption of digital health monitoring solutions, and the escalation of public-private partnerships focused on HIV management. Prominent trends expected in the forecast period include the growing uptake of antiretroviral therapy (ART), increased usage of both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), the broadening scope of HIV diagnostic and surveillance programs, an intensified focus on HIV vaccine research and development, and the integration of hospital and retail pharmacy services.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

What Drivers Are Affecting Demand In The Acquired Immunodeficiency Syndrome (AIDS) Market?

The escalating rates of HIV infections are anticipated to drive the expansion of the acquired immunodeficiency syndrome (AIDS) market in the coming years. HIV infections describe a condition caused by the human immunodeficiency virus (HIV), which targets the immune system, thereby reducing the body’s capability to fend off infections and diseases. The surge in HIV infection rates is attributed to factors like unprotected sexual intercourse with an infected person, sharing needles or syringes, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or pre-existing sexually transmitted infections. Acquired immunodeficiency syndrome (AIDS) management assists HIV infection patients by promoting early diagnosis, broadening access to effective antiretroviral therapies, strengthening prevention strategies, and enhancing healthcare systems, which collectively contribute to better control of the virus’s spread. For instance, in November 2024, according to data published by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, a total of 112,883 HIV diagnoses were reported in 2023 across 47 out of 53 countries in the region, with 24,731 cases recorded in the European Union/European Economic Area (EU/EEA). The overall crude rate of HIV diagnoses reached 12.7 per 100,000 population, marking a 2.4% increase compared to the 12.4 per 100,000 rate observed in 2022. Therefore, the increasing prevalence of HIV infections is a significant driver for the acquired immunodeficiency syndrome (AIDS) market.

Which Segment Groups Are Influencing The Acquired Immunodeficiency Syndrome (AIDS) Market?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

Which Competitive Trends Are Impacting The Structure Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are concentrating on the development of innovative therapies, such as long-acting injectables. These offer enhanced patient compliance, reduce the need for frequent dosing, and provide a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications delivered via injection that are engineered to release their active ingredients slowly over an extended duration, facilitating less frequent dosing compared to traditional oral medications. For instance, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that the European Commission had approved its long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered through intramuscular injection, typically every one or two months, depending on the specific treatment plan. The prolonged action of these injections may improve adherence rates among adolescents who encounter difficulties with daily pill regimens.

Who Are The Top-Performing Companies In The Acquired Immunodeficiency Syndrome (AIDS) Market In Recent Years?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Region Currently Holds The Largest Share Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Acquired Immunodeficiency Syndrome (AIDS) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Acne Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Walking Aids Market Report 2026

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795